Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Lilly, Daiichi Explore Pharmacogenomic Marker For Prasugrel

Executive Summary

A May 4 Circulation article describing prasugrel's efficacy in patients who carry a genetic marker indicative of non-response to Plavix may be the opening volley in one of the first big marketing battles of the personalized medicine era
Advertisement

Related Content

Effient Approval Was Prolonged, But FDA Requirements May Help Sponsors
Effient Approval Was Prolonged, But FDA Requirements May Help Sponsors
Effient Approval Shows Mark Of FDA Controls
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Effient Labeling Could Give Edge Against Plavix Through Pharmacogenetics
Last Gasp Or New Life? 2009’s Novel Products Have Blockbuster Potential
BMS/Sanofi-Aventis To Study Plavix Efficacy Concerns
Thrombosis Events Tied To Gene Mutation In Stent Patients On Clopidogrel
Lilly CEO Taurel Passes Baton To Lechleiter Effective April 1
Lilly’s Prasugrel Superior To Bristol’s Plavix In Reducing CV Events In Pivotal TRITON Trial

Topics

Advertisement
UsernamePublicRestriction

Register

PS051045

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel